By writer to www.streetinsider.com
Get immediate alerts when information breaks in your shares. Declare your 1-week free trial to StreetInsider Premium here.
SAN JOSE, Calif.–(BUSINESS WIRE)–
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical expertise firm pioneering a first-of-its-kind expertise to scale back the price and complexity of dialysis, introduced in the present day the pricing of an underwritten public providing of 4,000,000 shares of its frequent inventory by sure of its stockholders at a public providing worth of $53.00 per share. As well as, such promoting stockholders granted the underwriters a 30-day choice to buy as much as a further 600,000 shares of its frequent inventory on the public providing worth, much less the underwriting reductions and commissions. The underwriting reductions and commissions might be borne by the promoting stockholders. Outset is just not promoting any shares and won’t obtain any of the proceeds from the sale of the shares of frequent inventory being provided by the promoting stockholders. The providing is predicted to shut on December 7, 2020, topic to the satisfaction of customary closing circumstances.
BofA Securities, Morgan Stanley and Goldman Sachs & Co. LLC are appearing as joint lead book-running managers for the providing. SVB Leerink and Stifel are appearing as co-managers for the providing.
A registration assertion on Type S-1 regarding the shares being offered on this providing was filed with and declared efficient by the U.S. Securities and Alternate Fee. The providing is being made solely via a prospectus. When obtainable, a replica of the prospectus could also be obtained from BofA Securities, NC1-004-03-43, 200 North School Avenue, third Flooring, Charlotte, NC 28255-0001, Consideration: Prospectus Division, or by e mail at email@example.com; Morgan Stanley & Co. LLC, 180 Varick Avenue, 2nd Flooring, New York, NY 10014, Consideration: Prospectus Division, or by e mail at firstname.lastname@example.org; and Goldman Sachs & Co. LLC, Consideration: Prospectus Division, 200 West Avenue, New York, New York 10282, through phone: 1-866-471-2526, or through e mail: email@example.com.
This press launch shall not represent a proposal to promote or the solicitation of a proposal to purchase these securities, nor shall there be any sale of those securities in any state or jurisdiction through which such provide, solicitation or sale can be illegal previous to registration or qualification of those securities beneath the securities legal guidelines of any such state or jurisdiction.
About Outset Medical, Inc.
Outset is a medical expertise firm pioneering a first-of-its-kind expertise to scale back the price and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared to be used from the hospital to the house, represents a big technological development that transforms the dialysis expertise for sufferers and operationally simplifies it for suppliers. Tablo serves as a single enterprise answer that may be utilized throughout the continuum of care, permitting dialysis to be delivered anytime, wherever and by anybody. The combination of water purification and on-demand dialysate manufacturing allows Tablo to function a dialysis clinic on wheels, with 2-way wi-fi knowledge transmission and a proprietary knowledge analytics platform powering a brand new holistic method to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
This press launch incorporates forward-looking statements throughout the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended. These statements embrace statements concerning an providing of Outset Medical’s frequent inventory. Ahead-looking statements are inherently topic to dangers and uncertainties, a few of which can’t be predicted or quantified. These dangers and uncertainties, a lot of that are past our management, embrace dangers described within the part entitled Danger Components within the preliminary prospectus associated to this providing filed with the Securities and Alternate Fee. These forward-looking statements converse solely as of the date hereof and shouldn’t be unduly relied upon. Outset Medical disclaims any obligation to replace these forward-looking statements.
Lynn Lewis or Brian Johnston
Supply: Outset Medical, Inc.